Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
Bernie Sanders: 'Ozempic Will Likely Become One Of The Best-Selling Pharmaceutical Products In History' — Americans Shouldn't Pay 10-15X More
In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO).
最近，伯尼·桑德斯（參議員-Vt.）在一條推特中批評了主流藥物奧澤匹克的定價以及其製造商Novo Nordisk A/S（NYSE：NVO）
What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug's manufacturer, Novo Nordisk, will make billions of dollars from U.S. consumers annually, charging them 10-15 times more than people in other countries.
事件經過：週三，桑德斯在X（前稱Twitter）上表達了他對奧澤匹克定價的擔憂。他表示，該藥物的製造商諾和諾德公司將從美國消費者那裏每年收取10-15倍於其他國家的費用，從而獲得數十億美元的利潤。
Ozempic will likely become one of the best-selling pharmaceutical products in history.
— Bernie Sanders (@SenSanders) June 26, 2024
Its manufacturer, Novo Nordisk, will make billions of dollars from U.S. consumers every year.
Americans should not be charged 10-15x more for this drug than people in other countries.
奧澤匹克很可能成爲歷史上最暢銷的藥品之一。
— 伯尼·桑德斯（@BernieSanders）2024年6月26日
該藥的製造商諾和諾德公司將從美國消費者那裏每年獲得數十億美元的利潤。
美國人不應該爲這種藥物支付其他國家人的10-15倍價格。
"Ozempic will likely become one of the best-selling pharmaceutical products in history. Its manufacturer, Novo Nordisk, will make billions of dollars from U.S. consumers every year. Americans should not be charged 10-15x more for this drug than people in other countries," Sanders said.
“奧澤匹克很可能成爲歷史上最暢銷的藥品之一。該藥的製造商諾和諾德公司將從美國消費者那裏每年獲得數十億美元的利潤。美國人不應該爲這種藥物支付其他國家人的10-15倍價格。”桑德斯說。
Why It Matters: This isn't the first time Sanders has taken a stand against the high cost of Ozempic. In March, he criticized the "outrageous" prices of the drug and considered holding hearings on the issue. Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee, expressed concerns about the high cost of Ozempic, which is sometimes used controversially for weight loss by suppressing appetite.
爲高昂的奧澤匹克定價而站出來不是桑德斯第一次了。今年三月，他譴責了該藥物的“離譜”價格，並考慮就此問題舉行聽證會。擔任參議院健康、教育、勞工和養老金委員會主席的桑德斯表達了對奧澤匹克高昂價格的擔憂，該藥有時被用於抑制食慾以爭議的方式減肥。
Novo Nordisk CEO, Lars Fruergaard Jørgensen, agreed to testify before the Senate after Sanders threatened to subpoena the company over its pricing of Ozempic and the obesity drug Wegovy. This agreement followed a public dispute over scheduling a hearing, with Sanders' team claiming Novo was uncooperative, while the company said it was willing to testify.
諾和諾德公司CEO Lars Fruergaard Jørgensen在桑德斯威脅要傳喚該公司就其對奧澤匹克和肥胖藥物Wegovy的定價而接受了參議院的證詞。這項協議是在就聽證會的安排進行公開爭論後達成的，桑德斯的團隊聲稱諾和諾德公司沒有配合，而該公司則表示願意出席。
Price Action: On Wednesday, Novo Nordisk shares closed 2.2% lower at $143.67 in the regular session, according to Benzinga Pro data.
市場表現：據Benzinga Pro 數據顯示，週三，諾和諾德股價在常規交易中下跌2.2％，至143.67美元。
Photo by Joseph Sohm on Shutterstock
圖片來源於 shutterstock 的 Joseph Sohm。
This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal
本報道使用Benzinga Neuro生成，並由Shivdeep Dhaliwal
譯文內容由第三人軟體翻譯。